Clinical Landscape in Cancer Research

Ranjita Shegokar · Yashwant Pathak

2025年3月 · Academic Press

電子書

320

頁數

符合資格

評分和評論未經驗證瞭解詳情

關於這本電子書

Cancer, a multifaceted disease, remains the leading cause of death worldwide. Ongoing research and technological advancements are continually improving the human understanding of newer treatment options. This book series aims to provide wide-ranging insights into the current landscape of cancer research, highlighting the recent advancements, current challenges, and future directions. Cancer varies widely in its formation, microenvironment, location in the body, associated risk factors, detection methodology, and treatment approaches. Early detection and prevention through lifestyle changes, regular screenings, and the awareness of symptoms are crucial for improving outcomes and survival rates. In this book series, the main focus is on trending topics, like new drug delivery, diagnostics, biomarkers, and preclinical and clinical developments in cancer research. Nanotechnology has emerged as a transformative approach in medicine, particularly in the areas of targeted drug delivery systems, imaging, and diagnostics to enhance the therapeutic efficacy and minimize adverse effects in cancer therapy. Advances in pharma, medical device, and diagnostic research, including the development of Trojan-horse therapies and precision treatments/assay kits, continue to enhance the effectiveness of cancer care over the past few decades. A total of five books are covered in this series: - Drug Delivery Landscape in Cancer Research (Vol. 1) - Biomarker Landscape in Cancer Research (Vol. 2) - Diagnostic Landscape in Cancer Research (Vol. 3) - Preclinical Landscape in Cancer Research (Vol. 4) - Clinical Landscape in Cancer Research (Vol. 5) By integrating basic, applied, and innovative science concepts, this book series fosters a deeper understanding of the disease and paves the way for the development of more effective strategies. This book series serves as a valuable resource for students, researchers, regulators, and clinicians interested in understanding the complexities of cancer and the innovative approaches researched to combat this deadly disease. Nonetheless, continuous interdisciplinary, cross-country collaborations and cross-science innovation strategies are essential to further reduce the global cancer burden. - Contains current studies of the clinical research of different cancer types - Provides essential information on the most recent developments in clinical cancer research - Explains current technology and its applications of clinical cancer research - Holds contributions from oncologists, biomedical engineers, pharmaceutical scientists, and manufacturers

關於作者

Ranjita Shegokar holds a Ph.D. degree in Pharmaceutical Technology from the SNDT University, India, and has been a postdoctoral researcher in the Department of Pharmaceutics, Biopharmaceutics and NutriCosmetics at the Free University of Berlin, Germany. Currently, she serves as Chief Scientific Officer (CSO) at Capnopharm GmbH, Germany. She has authored several research articles, book chapters, and presented her research in many national/international conferences. She has filed multiple patent applications in the area of drug delivery and targeting. Besides that, she has edited many trending books in the area of pharmaceutical nanotechnology and drug delivery aspects. For her research, she has received many prestigious national and international awards among them include recently received prestigious German Innovation Award 2022. Her areas of interest include polymeric nanoparticles, nanocrystals, lipid nanoparticles (SLNs/NLCs), nanoemulsions, cancer drug targeting and the role of excipients in delivery systems. (www.ranjitas.com)

Yashwant Pathak is a Professor and Associate Dean for faculty affairs at the Taneja College of Pharmacy at the University of South Florida, Tampa, USA. Prof. Pathak is also an Adjunct Professor at the Faculty of Pharmacy, Airlangga University, Surabaya, Indonesia. His area of research is in health care education, nanotechnology, drug delivery systems, and nutraceuticals.